MX2019000342A - Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. - Google Patents

Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.

Info

Publication number
MX2019000342A
MX2019000342A MX2019000342A MX2019000342A MX2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A
Authority
MX
Mexico
Prior art keywords
compositions
treating
diseases
methods
lysosomal storage
Prior art date
Application number
MX2019000342A
Other languages
English (en)
Inventor
D Claypool William
Original Assignee
Ranedis Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranedis Pharmaceuticals Llc filed Critical Ranedis Pharmaceuticals Llc
Publication of MX2019000342A publication Critical patent/MX2019000342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención incluye composiciones para tratar una enfermedad o trastorno de almacenamiento lisosomal y métodos que las usan; en ciertas modalidades, las composiciones de la invención comprenden un inhibidor de la histona desacetilasa (HDACi), una ciclodextrina, agua, opcionalmente un polialquileno glicol y opcionalmente dimetil sulfóxido (DMSO); en otras modalidades, las composiciones de la invención comprenden una HDACi, una ciclodextrina, agua, un polialquileno glicol y DMSO.
MX2019000342A 2016-07-08 2017-07-05 Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. MX2019000342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360012P 2016-07-08 2016-07-08
US201762513231P 2017-05-31 2017-05-31
PCT/US2017/040703 WO2018009531A1 (en) 2016-07-08 2017-07-05 Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases

Publications (1)

Publication Number Publication Date
MX2019000342A true MX2019000342A (es) 2019-09-04

Family

ID=60913099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000342A MX2019000342A (es) 2016-07-08 2017-07-05 Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.

Country Status (9)

Country Link
US (1) US20190224146A1 (es)
EP (1) EP3481376A4 (es)
JP (1) JP2019524879A (es)
CN (1) CN109715141A (es)
AU (1) AU2017292776A1 (es)
CA (1) CA3030142A1 (es)
IL (1) IL264124A (es)
MX (1) MX2019000342A (es)
WO (1) WO2018009531A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226939A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2008531708A (ja) * 2005-02-28 2008-08-14 コーザン バイオサイエンシス インコーポレイテッド １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤
PL1901729T3 (pl) * 2005-05-13 2012-07-31 Topotarget Uk Ltd Formulacje farmaceutyczne inhibitorów hdac
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
ITRM20070038A1 (it) * 2007-01-26 2008-07-27 Uni Degli Studi Di Roma La Sapienza Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
WO2012162535A1 (en) * 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
EP3102291A4 (en) * 2014-02-04 2017-08-30 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
WO2015191931A1 (en) * 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
AU2017242544B2 (en) * 2016-03-31 2022-11-24 Midatech Ltd. Cyclodextrin-panobinostat adduct
CN106963752A (zh) * 2017-04-13 2017-07-21 广州赛加生物科技有限公司 一种含有组氨酸去乙酰化酶抑制剂衍生物的抗肿瘤药物

Also Published As

Publication number Publication date
CN109715141A (zh) 2019-05-03
JP2019524879A (ja) 2019-09-05
AU2017292776A1 (en) 2019-02-21
IL264124A (en) 2019-02-28
EP3481376A1 (en) 2019-05-15
US20190224146A1 (en) 2019-07-25
EP3481376A4 (en) 2020-04-08
CA3030142A1 (en) 2018-01-11
WO2018009531A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
HK1251571A1 (zh) 作為組蛋白脫乙酰基酶6抑制劑的1，3，4-噁二唑磺酰胺衍生化合物及含有其的醫藥組合物
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
HK1254756A1 (zh) 作為組蛋白脫乙酰酶6抑制劑的1，3，4-噁二唑衍生物化合物及包含其的藥物組合物
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
DK3328844T3 (da) 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme
MX2017014299A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
BR112015023434A2 (pt) inibidores de histona deacetilase
TW201625535A (en) Inhibitors of histone demethylases
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
MX2019007346A (es) Inhibidores de histona deacetilasa.
DK3833682T3 (da) Selvmordsmolekyle sammensætninger og fremgangsmåder
CL2019001760A1 (es) Composiciones que comprenden ácido acético y ácido hipoclórico y métodos para tratar una biopelícula.
BR112017028139A2 (pt) inibidores de histona desacetilase
WO2019032528A8 (en) BICYCLIC HISTONE DEACETYLASE INHIBITORS
DK3478310T3 (da) Sammensætninger, som er anvendelige inden for forebyggelsen og/eller behandlingen af osteoartikulær inflammation og smerte samt bruskskade
UY38352A (es) Inhibidores de integrina alfavbeta6
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
MX2019000342A (es) Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.
EP3257497C0 (en) ANTIOXIDANT, ANTIOXIDANT COSMETIC AND UV CARE COSMETIC BASED ON ENZYMATICALLY SYNTHETIZED GLYCOGEN OR AN ALPHA-AMYLASE DIGESTION THEREOF